Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | February 02, 2018 | February 06, 2018 |
| Assertio Therapeutics, IncDEPO · Entity 149352 | Director · President and CEO | December 31, 2016 | February 11, 2017 |
| Calidi Biotherapeutics, Inc.CLDI · Entity 8408 | Director | August 17, 2026 | August 19, 2026 |
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | Director | March 16, 2026 | March 16, 2026 |
| KYNTRA BIO, INC.KYNB · Entity 7431 | Director | June 12, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 02, 2018 · Filed February 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.81 · Expires 2028-02-01 | Direct | 6,000 |
Reported balance
After 2018-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-02 · Grant · Acquired 6,000 · Balance 6,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
Assertio Therapeutics, Inc
Report date December 31, 2016 · Filed February 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 495,105 |
Reported balance
After 2016-10-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-10-12 · Gift · Disposed 2,000 · Balance 495,105 F1: Charitable transfer of shares from family trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Charitable transfer of shares from family trust.
Calidi Biotherapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-08-17 | Direct | 5,000 |
Reported balance
After 2026-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 5,000 · Balance 5,000 F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F2: Does not include the stock options previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.
F2: Does not include the stock options previously granted to the Reporting Person.
Connect Biopharma Holdings Ltd
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2035-07-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The stock option vests and becomes exercisable over three years, with 1/3 vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next two years. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2036-03-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The stock option fully vests and becomes exercisable on March 2, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable over three years, with 1/3 vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next two years.
F2: The stock option fully vests and becomes exercisable on March 2, 2027.
KYNTRA BIO, INC.
Report date June 12, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2036-06-11 | Direct | 7,000 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 7,000 · Balance 7,000 F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2019 Filed May 10, 2019 01:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 500 | $47.69 | $23,845.00 |
DisclosureSEC source: 0001209191-19-028663 · doc4.xml · nonDerivative · entry 3 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $47.27 to $48.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2019 Filed May 10, 2019 01:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,500 | $46.80 | $70,200.00 |
DisclosureSEC source: 0001209191-19-028663 · doc4.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $46.16 to $47.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2019 Filed May 10, 2019 01:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 2,000 | $2.90 | $5,800.00 |
DisclosureSEC source: 0001209191-19-028663 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:43 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-024314 · doc4.xml · derivative · entry 3 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:43 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $52.90 | $105,800.00 |
DisclosureSEC source: 0001209191-19-024314 · doc4.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $52.69 to $53.27. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:43 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 2,000 | $2.90 | $5,800.00 |
DisclosureSEC source: 0001209191-19-024314 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-018278 · doc4.xml · derivative · entry 4 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 380 | $55.23 | $20,987.40 |
DisclosureSEC source: 0001209191-19-018278 · doc4.xml · nonDerivative · entry 3 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $55.05 to $55.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,620 | $54.62 | $88,484.40 |
DisclosureSEC source: 0001209191-19-018278 · doc4.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,080 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $54.05 to $55.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 2,000 | $2.90 | $5,800.00 |
DisclosureSEC source: 0001209191-19-018278 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2019 Filed Feb 9, 2019 00:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-008746 · doc4.xml · derivative · entry 3 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 2,000 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 07, 2019 Filed Feb 9, 2019 00:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $57.17 | $114,340.00 |
DisclosureSEC source: 0001209191-19-008746 · doc4.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| February 07, 2019 Filed Feb 9, 2019 00:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 2,000 | $2.90 | $5,800.00 |
DisclosureSEC source: 0001209191-19-008746 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 23:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-003154 · doc4.xml · derivative · entry 3 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 2,000 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 23:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $45.90 | $91,800.00 |
DisclosureSEC source: 0001209191-19-003154 · doc4.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 23:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 2,000 | $2.90 | $5,800.00 |
DisclosureSEC source: 0001209191-19-003154 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 17:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (RIght to Buy) · Derivative | 12,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056739 · doc4.xml · derivative · entry 4 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 17:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001209191-18-056739 · doc4.xml · derivative · entry 3 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2023-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 17:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $18.00 | $216,000.00 |
DisclosureSEC source: 0001209191-18-056739 · doc4.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 17:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $9.78 | $117,300.00 |
DisclosureSEC source: 0001209191-18-056739 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2018 Filed Jul 7, 2018 00:04 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,639 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-041916 · doc4.xml · derivative · entry 3 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 7,639 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| July 03, 2018 Filed Jul 7, 2018 00:04 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,639 | $65.00 | $496,535.00 |
DisclosureSEC source: 0001209191-18-041916 · doc4.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| July 03, 2018 Filed Jul 7, 2018 00:04 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 7,639 | $2.90 | $22,153.10 |
DisclosureSEC source: 0001209191-18-041916 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,361 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-039547 · doc4.xml · derivative · entry 3 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,639 Underlying: Common Stock · 4,361 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,361 | $65.00 | $283,465.00 |
DisclosureSEC source: 0001209191-18-039547 · doc4.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,361 | $2.90 | $12,646.90 |
DisclosureSEC source: 0001209191-18-039547 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $55.30 | $0.00 |
DisclosureSEC source: 0001209191-18-036521 · doc4.xml · derivative · entry 2 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-05 F2 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036521 · doc4.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| February 02, 2018 Filed Feb 6, 2018 21:18 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $104.81 | $0.00 |
DisclosureSEC source: 0001209191-18-007835 · doc4.xml · derivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:43 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001209191-17-039003 · doc4.xml · derivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable quarterly over one year measured from June 7, 2017. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:59 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015465 · doc4.xml · derivative · entry 1 Schoeneck James A · CIK 0001420987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The stock option vests and becomes fully exercisable on February 24, 2018. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:39 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantStock Options · Derivative | 245,000 | $0.00 Strike: $17.09 | $0.00 |
DisclosureSEC source: 0001179110-17-002204 · edgar.xml · derivative · entry 2 Schoeneck James A · CIK 0001420987 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 245,000 shares Expires 2027-02-08 F3 · derivative.exercise_date: These stock options are exercisable in 48 equal monthly installments. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:39 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantRestricted Stock Units · Derivative | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002204 · edgar.xml · derivative · entry 1 Schoeneck James A · CIK 0001420987 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019, and 25% on December 1, 2020, assuming continued employment through the applicable vesting date. F2 · derivative.expiration_date: These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019, and 25% on December 1, 2020, assuming continued employment through the applicable vesting date. Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 21:21 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GiftCommon Stock | 61,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033463 · edgar.xml · nonDerivative · entry 2 Schoeneck James A · CIK 0001420987 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 495,105 F1 · kind: Transfer of shares to family trust. F1 · shares: Transfer of shares to family trust. Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 21:21 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GiftCommon Stock | 61,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033463 · edgar.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transfer of shares to family trust. F1 · shares: Transfer of shares to family trust. Read SEC document |
| December 01, 2016 Filed Dec 6, 2016 23:59 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | Tax withholdingCommon Stock | 66,793 | $18.55 | $1,239,010.15 |
DisclosureSEC source: 0001179110-16-032500 · edgar.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,207 F1 · shares: Represents shares of restricted stock forfeited to meet the tax liability triggered by the vesting of such restricted stock. F2 · balance_after: Amount does not include any unvested restricted stock previously reported on Form 4 by the reporting person. F3 · balance_after: Amount does not include 433,898 shares of common stock held indirectly by family trust. Read SEC document |
| October 12, 2016 Filed Feb 11, 2017 00:40 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002206 · edgar.xml · nonDerivative · entry 1 Schoeneck James A · CIK 0001420987 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 495,105 F1 · price: Charitable transfer of shares from family trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.